Belite Bio has started a rolling New Drug Application submission to the FDA for its oral therapy tinlarebant, targeting Stargardt disease type 1. The filing follows the positive topline results from the Phase 3 DRAGON trial, which showed a 36% reduction in retinal lesion growth versus placebo and met its primary efficacy endpoint.
Tinlarebant has received Breakthrough Therapy Designation, Fast Track, and Rare Pediatric Disease Designations in the U.S., and orphan drug status in the U.S., Europe, and Japan. The drug works by lowering serum retinol binding protein 4, reducing accumulation of bisretinoids in the eye.
The company’s financial performance in 2025 reflected heavy investment in research and development. Net loss for the full year was $77.61 million, up from $36.14 million a year earlier, driven by R&D expenses of $9.4 million (up from $6.8 million) and G&A expenses of $6.1 million (up from $1.6 million). Belite Bio ended 2025 with $772.6 million in cash and equivalents after a $402 million public offering.
Management highlighted the significance of the FDA filing. Dr. Tom Lin, Chairman and CEO, said the data package, including the DRAGON trial results, positions tinlarebant as a potential first‑in‑class therapy and signals readiness to submit the NDA in the second quarter of 2026. Dr. Hendrik Scholl, Chief Medical Officer, emphasized the impact on patients, noting that tinlarebant could become the first approved treatment for a disease that currently has no therapy.
The Stargardt disease market is sizable and growing. A 2025 report valued the global market at $1.8 billion, with projections of $3.5 billion by 2034 and a CAGR of 7.5%. Competition includes gene therapies and other small‑molecule antagonists from companies such as Ascidian Therapeutics and Ocugen.
Analysts have maintained positive outlooks. H.C. Wainwright, Benchmark, and Mizuho all reaffirmed buy ratings, citing the company’s strong cash position and regulatory progress.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.